Mizuho Increases Cardinal Health (NYSE:CAH) Price Target to $120.00

Cardinal Health (NYSE:CAH) had its price target upped by Mizuho from $110.00 to $120.00 in a report released on Monday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Mizuho’s price objective indicates a potential upside of 6.03% from the company’s previous close.

CAH has been the topic of a number of other research reports. StockNews.com lowered Cardinal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Barclays raised their price objective on Cardinal Health from $117.00 to $133.00 and gave the stock an “overweight” rating in a research note on Monday. JPMorgan Chase & Co. raised their price objective on Cardinal Health from $111.00 to $123.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Wells Fargo & Company raised their price objective on Cardinal Health from $95.00 to $101.00 and gave the stock an “underweight” rating in a research note on Thursday, August 15th. Finally, Evercore ISI lifted their price target on Cardinal Health from $105.00 to $115.00 and gave the company an “in-line” rating in a research note on Thursday, August 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

Cardinal Health Trading Up 1.1 %

Shares of NYSE CAH opened at $113.18 on Monday. The firm has a market cap of $27.39 billion, a P/E ratio of 22.02, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. Cardinal Health has a 1-year low of $93.17 and a 1-year high of $119.13. The business’s 50 day moving average is $111.79 and its 200-day moving average is $104.20.

Cardinal Health (NYSE:CAH) last posted its quarterly earnings data on Friday, November 1st. The company reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.26. Cardinal Health had a negative return on equity of 56.56% and a net margin of 0.56%. The firm had revenue of $52.28 billion for the quarter, compared to analyst estimates of $50.90 billion. During the same quarter last year, the company earned $1.73 EPS. The company’s revenue was down 4.3% on a year-over-year basis. Analysts forecast that Cardinal Health will post 7.69 EPS for the current year.

Insider Activity at Cardinal Health

In related news, CEO Jason M. Hollar sold 46,455 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $109.02, for a total transaction of $5,064,524.10. Following the sale, the chief executive officer now owns 197,636 shares of the company’s stock, valued at $21,546,276.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Cardinal Health news, CEO Jason M. Hollar sold 46,455 shares of Cardinal Health stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $109.02, for a total transaction of $5,064,524.10. Following the transaction, the chief executive officer now directly owns 197,636 shares of the company’s stock, valued at approximately $21,546,276.72. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Aaron E. Alt sold 2,323 shares of Cardinal Health stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $108.91, for a total value of $252,997.93. Following the transaction, the chief financial officer now directly owns 36,867 shares in the company, valued at $4,015,184.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 113,963 shares of company stock valued at $12,379,980 in the last 90 days. 0.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its position in shares of Cardinal Health by 379.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 106,105 shares of the company’s stock worth $11,873,000 after acquiring an additional 83,975 shares in the last quarter. Private Advisor Group LLC raised its position in shares of Cardinal Health by 13.4% in the 1st quarter. Private Advisor Group LLC now owns 12,077 shares of the company’s stock worth $1,350,000 after acquiring an additional 1,428 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Cardinal Health by 34.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 85,580 shares of the company’s stock worth $9,576,000 after acquiring an additional 21,801 shares in the last quarter. Graypoint LLC bought a new position in shares of Cardinal Health in the 1st quarter worth about $265,000. Finally, Daiwa Securities Group Inc. raised its position in shares of Cardinal Health by 37.6% in the 1st quarter. Daiwa Securities Group Inc. now owns 37,753 shares of the company’s stock worth $4,224,000 after acquiring an additional 10,317 shares in the last quarter. 87.17% of the stock is owned by institutional investors and hedge funds.

Cardinal Health Company Profile

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.